Quick Answer
AGIOS PHARMACEUTICALS, INC. reported Cash And Cash Equivalents At Carrying Value of $89.13 million for the year ending 2025.
- AGIOS PHARMACEUTICALS, INC. showed an increase of +16.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from AGIOS PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2012: $96.12 million | Q3 2012: $83.04 million | Q1 2013: $83.38 million | Q2 2013: $77.48 million | Q3 2013: $106.01 million | Q1 2014: $32.84 million | Q2 2014: $108.25 million | Q3 2014: $70.05 million | Q1 2015: $35.26 million | Q2 2015: $72.53 million | Q3 2015: $80.05 million | Q1 2016: $39.04 million | Q2 2016: $234.05 million | Q3 2016: $285.50 million | Q1 2017: $200.28 million | Q2 2017: $138.72 million | Q3 2017: $132.74 million | Q1 2018: $364.47 million | Q2 2018: $210.32 million | Q3 2018: $156.48 million | Q1 2019: $103.44 million | Q2 2019: $83.58 million | Q3 2019: $81.71 million | Q1 2020: $89.09 million | Q2 2020: $295.86 million | Q3 2020: $104.86 million | Q1 2021: $1.89 billion | Q2 2021: $969.12 million | Q3 2021: $400.22 million | Q1 2022: $80.03 million | Q2 2022: $88.54 million | Q3 2022: $122.45 million | Q1 2023: $104.14 million | Q2 2023: $84.75 million | Q3 2023: $64.33 million | Q1 2024: $118.76 million | Q2 2024: $84.52 million | Q3 2024: $253.73 million | Q1 2025: $78.96 million | Q2 2025: $80.87 million | Q3 2025: $92.71 million.
- Over the full 16 years of available data (2010 to 2025), AGIOS PHARMACEUTICALS, INC.'s Cash And Cash Equivalents At Carrying Value has grown by 14.4%.
- Historical annual values: Fiscal year 2025: $89.13 million | Fiscal year 2024: $76.25 million | Fiscal year 2023: $88.21 million | Fiscal year 2022: $139.26 million | Fiscal year 2021: $203.13 million | Fiscal year 2020: $127.44 million | Fiscal year 2019: $80.93 million | Fiscal year 2018: $70.50 million | Fiscal year 2017: $102.72 million | Fiscal year 2016: $160.75 million | Fiscal year 2015: $71.76 million | Fiscal year 2014: $14.03 million | Fiscal year 2013: $71.56 million | Fiscal year 2012: $91.30 million | Fiscal year 2011: $117.66 million | Fiscal year 2010: $77.88 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: